Mercy BioAnalytics Raises $59 Million Series B to Advance Cancer Detection Platform
The funding will support commercialization of the company’s extracellular vesicle-based liquid biopsy tests, starting with ovarian cancer screening.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
